- €264.38m
- €290.94m
- €62.58m
Brief: Lavipharm To Acquire Durogesic Pain Patch Rights From Janssen For $12.0 Million
Brief: Lavipharm SA FY 2025 Earnings After Tax EUR 6.0 Million Versus EUR 9.0 Million Year Ago
Brief: Lavipharm 9-Month Net Profit Down To EUR 3.5 Million
Brief: Lavipharm H1 Adjusted EBITDA At EUR 7.7 Million, Up 29.4% YoY
Brief: Lavipharm To Distribute Dividend Of EUR 0.02 Per Share
Brief: Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY
Brief: Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company
Brief: Lavipharm FY 2024 Earnings After Tax EUR 9.0 Million Versus EUR 1.87 Million Year Ago
Brief: Lavipharm Signs Strategic Commercial Agreement With iNova Pharmaceuticals
Brief: Lavipharm 9-Month Adjusted EBITDA At EUR 9.1 Million, Up 21.2% YoY
Brief: Lavipharm H1 Net Profit Up At EUR 7.7 Million
Brief: Lavipharm Q1 Net Profit Up At EUR 1.1 Million
Brief: Lavipharm FY 2023 Net Profit Up At EUR 1.9 Million
Brief: Lavipharm Announces The Launch Of The First Locally Produced Cannabis-Based Prescription Medicine
Brief: Lavipharm Announces The Cessation Of The Group’s Pharmaceutical Wholesale Activities And Logistics Services (3PL)
Brief: Lavipharm Signs An Asset Purchase Agreement With Sanofi For The Acquisition Of Flagyl For The Greek Market
Brief: Lavipharm Signs Asset Purchase Agreement With Boehringer Ingelheim For The Acquisition Of Two Analgesic Pharmaceutical Products
Brief: Lavipharm 9-Month Net Profit At EUR 2.1 Million, Down 21.6% YoY
Brief: Lavipharm H1 Net Profit Up To EUR 2.2 Million